Axonyx Completes Multiple Dose Safety Trial For Its Lead Alzheimer's Drug.Health/Medical & Business Editors NEW YORK--(BW HealthWire)--Sept. 12, 2000 Axonyx Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :AXYX) announced today results from a multiple dose Phase I human safety trial for Phenserine, the Company's lead drug for Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . In this study, which follows the Company's successful single dose Phase I trial, the Company identified a therapeutic range for the oral administration of multiple doses of the drug. This second Phase I trial confirmed preclinical findings with Phenserine, demonstrated patient safety and showed a significant inhibition of red blood cell red blood cell: see blood. acetylcholinesterase acetylcholinesterase /ac·e·tyl·cho·lin·es·ter·ase/ (AChE) (-ko?li-nes´ter-as) an enzyme present in the central nervous system, particularly in nervous tissue, muscle, and red cells, that catalyzes the hydrolysis of acetylcholine to . Inhibition of this enzyme in brain is associated with improvement of memory and cognition cognition Act or process of knowing. Cognition includes every mental process that may be described as an experience of knowing (including perceiving, recognizing, conceiving, and reasoning), as distinguished from an experience of feeling or of willing. in patients with Alzheimer's Disease. Phenserine is a highly selective, reversible acetylcholinesterase inhibitor acetylcholinesterase inhibitor n. See cholinesterase inhibitor. which may offer an alternative to drugs currently marketed for Alzheimer's Disease. This drug is unique in its preferential distribution and retention in the brain while disappearing rapidly from the blood. "These results confirm that Phenserine is a safe and well tolerated drug, and encourages us to start a Phase II proof-of-concept/efficacy trial in patients with Alzheimer's Disease. Axonyx intends to commence this Phase II trial before the end of the year with completion expected during 2001," commented Marvin S. Hausman, M.D., Axonyx's President and Chief Executive Officer. Axonyx Inc. is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders. This press release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. or predictions. These statements represent our judgment as of this date and are subject to risks and uncertainties that could materially affect the Company. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion